Sanofi-Aventis and Bioventus Products Globally Preferred to Treat Resilient Knee and Hip Pain for Sports Medicine and Osteoarthritis Applications
Globally, hyaluronic acid viscosupplementation products must rely on clinical efficacy, as healthcare practitioners are not particularly responsive to branding or purchasing incentives, according to iData Research's Sports Medicine Survey.
Vancouver, BC (PRWEB) August 18, 2014
According to a sports medicine survey conducted by iData Research (http://www.idataresearch.com) at the American Academy of Orthopaedic Surgeons (AAOS) conference, healthcare practitioners from around the world were surveyed on hyaluronic acid viscosupplementation product and brand preferences, as well as treatment options. More than 200 healthcare practitioners were surveyed and, of those respondents over 75% were actively involved in performing knee and hip repairs.
Attendees from North, South, and Central America showed a preference for Sanofi-Aventis’ Synvisc® predominantly, and Synvisc-One® secondarily. Across Europe and in the Middle East, AAOS attendees showed preferences for DUROLANE® by Bioventus, with Synvisc® taking a secondary brand preference position.
“The healthcare practitioners who attended the AAOS conference showed a distinct preference towards three injection cycle products, like Synvisc® from Sanofi-Aventis,” explains Kamran Zamanian, President and CEO of iData. “Our survey also revealed that clinical efficacy is the predominant reason for a practitioner to choose a brand for HA (hyaluronic acid) viscosupplementation.” While hyaluronic acid has a number of uses, ranging from the orthopedic therapy to cosmetic applications, it is very frequently used to treat knee pain that has not adequately responded to pain killers. This makes it especially relevant in the field of sports medicine.
Among a global spectrum of survey participants, purchasing incentives provided by manufacturers were shown to have little sway. Some Western Europe healthcare practitioners found bulk purchasing discounts attractive.
The iData Global Sports Medicine Physician Survey also asked AAOS attendees from around the world regarding their brand preferences for and usage rates for platelet rich plasma and concentrated bone marrow aspirate, including frequency of usage when treating tendonitis/tendonosis and osteoarthritis.
Countries represented by AAOS attendees include the United States, Canada, the United Kingdom, Spain, Denmark, France, the Netherlands, Belgium, Lithuania, Turkey, Estonia, Serbia, Argentina, Brazil, Colombia, Venezuela, Peru, Bolivia, Ecuador, Honduras, El Salvador, Mexico, the Dominican Republic, Jordan, Isreal, Saudi Arabia, Iran, Nigeria, South Africa, Egypt, Thailand, Malaysia, India, China, the Philippines, and South Korea.
For more information
The data used in this article is derived from iData Research report entitled 2014 Global Sports Medicine Physician Survey. Visit iData’s website for more details about this report.
About iData Research
iData Research (http://www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology, Urology and more.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/08/prweb12099797.htm